Showing results (451-460 of 493) with videos related to

Sort By:
Pageof 50
Cell Communication and Signaling : CCS|March 28, 2024
M1-derived extracellular vesicles polarize recipient macrophages into M2-like macrophages and alter skeletal muscle homeostasis in a hyper-glucose environmentStefano Tacconi, Francesco Vari, Carolina Sbarigia, et al.
Leukemia|July 8, 2020
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myelomaMarco Rossi, Emanuela Altomare, Cirino Botta, et al.
Blood|July 13, 2018
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92Eugenio Morelli, Lavinia Biamonte, Cinzia Federico, et al.
British Journal of Haematology|July 3, 2026
Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experienceAndrea Duminuco, Dario Leotta, Alessandro Allegra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 5, 2012
Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidenceMaria T Di Martino, Emanuela Leone, Nicola Amodio, et al.
Frontiers in Oncology|December 3, 2021
TERT Promoter Mutations and rs2853669 Polymorphism: Useful Markers for Clinical Outcome Stratification of Patients With Oral Cavity Squamous Cell CarcinomaSilvia Giunco, Paolo Boscolo-Rizzo, Enrica Rampazzo, et al.
Molecular Cancer Therapeutics|April 27, 2013
Identification and characterization of a small-molecule inhibitor of Wnt signaling in glioblastoma cellsAlessandra De Robertis, Silvia Valensin, Marco Rossi, et al.
Experimental Hematology & Oncology|September 12, 2022
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström MacroglobulinemiaEugenio Morelli, Zachary R Hunter, Mariateresa Fulciniti, et al.
The Journal of Investigative Dermatology|March 30, 2023
A Spontaneous Melanoma Mouse Model Applicable for a Longitudinal Chemotherapy and Immunotherapy StudyKevinn Eddy, Kajal Gupta, Jeffrey C Pelletier, et al.
Eclinicalmedicine|July 3, 2023
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencingStefania Oliva, Elisa Genuardi, Laura Paris, et al.
Pageof 50